Dr. Christine Reynet is currently co-Director and co-Owner of McC+R&D Consulting Ltd, a UK-based Pharmaceutical Consultancy company that she co-founded in 2009 with Dr. Jim McCormack. McC+R&D Consulting’s main activities are to consult for and advise world-wide based clients, principally from the Pharma / Biotech / Start-up industries, mainly in the Metabolic diseases area, covering all scientific, strategic and operational aspects of the process of Drug Discovery and Early Development, from basic research to drug candidate profiling and development. [www.mccrd-consulting.com]
Christine has over 20 years extensive experience in Drug Discovery - both in Biotech and Big Pharma - and in Research, particularly in Diabetes and related Metabolic Diseases. She has a well demonstrated expertise in initiating, driving and delivering innovative projects, and also in the evaluation of a large variety of opportunities, including on development of industry/academia collaborations to bridge the innovation gap.
Prior to McC+R&D Consulting, Christine was Senior Director and Head of Biology at (OSI) Prosidion, Oxford, UK. She was directly involved in the strategic direction of Discovery Research and was also leading a highly performing Biology Department. Christine joined (OSI) Pharmaceuticals Inc. in 2002 and was one of the founders of Prosidion Ltd. in 2003, a spin-out then subsidiary of (OSI) Pharmaceuticals, expanding and developing the Biology Dept and the Research organisation, focusing on the discovery and development of safer, more effective, innovative small molecules for the treatment of type 2 diabetes and obesity. During her 5 years at (OSI) Prosidion, she was a key player in the identification and progression of 4 novel compounds into development, and also in successful out-licensing.
Prior to Prosidion, Christine was Principal Scientist in Discovery Research at Novo Nordisk A/S, Denmark (1994-2002), where she ran a research group focusing on developing directly relevant model systems for studying the cellular mechanism of action of anti-diabetic drugs, and she initiated and/or developed several collaborations for novel exploratory projects targeting new therapies for type 2 diabetes. She was also Project Leader of external collaborations with Biotechs assessing novel technologies. In addition, she participated, as Management Committee Member and Danish Delegate, in European Commission programmes on “Insulin Resistance, Obesity and Type 2 Diabetes”.
Before joining Novo Nordisk, Christine was a Harvard Medical Research Fellow in Dr. Ron Kahn’s laboratory at the Joslin Diabetes Center, Boston, USA (1991-1994). She obtained her Ph.D. in 1990 in Molecular and Cellular Endocrinology from Pierre and Marie Curie University, Paris, France, after her M.Sc. in Endocrinology and B.Sc. in Cellular Biology and Genetics. She has also published numerous articles, and regularly gives talks and seminars.